Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prognostic Stage III Breast Cancer AJCC v8: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Prognostic Stage III Breast Cancer AJCC v8: 2 US clinical trials tracked, none currently recruiting.
Prognostic Stage III Breast Cancer AJCC v8 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition prognostic-stage-iii-breast-cancer-ajcc-v8
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Prognostic Stage III Breast Cancer AJCC v8 has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prognostic Stage III Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prognostic Stage III Breast Cancer AJCC v8 is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prognostic Stage III Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prognostic Stage III Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prognostic Stage III Breast Cancer AJCC v8 page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Prognostic Stage III Breast Cancer AJCC v8 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Alliance for Clinical Trials in Oncology sponsors the most Prognostic Stage III Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prognostic Stage III Breast Cancer AJCC v8 condition card totals 2 registered trials; most-linked intervention Text Message-based Navigation Intervention; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.